Preclinical and early clinical studies demonstrate that dual inhibition—such as combining MEK and PI3K inhibitors—can induce synergistic apoptosis and tumor regression, particularly in tumors harboring KRAS, BRAF, or PIK3CA mutations. Here, PIK3CB is linked to neoplasm.